Page last updated: 2024-08-17

quinoxalines and Rosacea

quinoxalines has been researched along with Rosacea in 19 studies

Research

Studies (19)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	19 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fowler, J; Jackson, M; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M	1
Del Rosso, JQ	1
Kempers, S; Leoni, M; Liu, H; Moore, A; Murakawa, G; Swinyer, L; Tauscher, A; Weiss, J	1
Levitt, JO; Routt, ET	1
Benkali, K; Bouer, R; Fernando, A; Graeber, M; Leoni, M; Rony, F; Wagner, N	1
Berson, D; Del Rosso, JQ; Eichenfield, LF; Gallo, R; Stein-Gold, L; Tanghetti, E; Thiboutot, D; Webster, G; Zaenglein, A	1
Ilkovitch, D; Pomerantz, RG	1
Fowler, J; Jackson, JM; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M	1
Kalowitz, A; Markowitz, O; Meekings, A; Siripunvarapon, AH; Urban, J	1
Moore, AY; Tong, LX	1
Fowler, J	1
Hougeir, FG	1
Feldman, SR; Moustafa, FA; Sandoval, LF	1
Belasco, KT; Cadena, MJ; Friedrichs, A; Hinek, A; Hong, HC; Hougier, F; Jackson, JM; Johnson, SM; Kerdel, FA; Palceski, D; Tanghetti, EA	1
Carter, B; Charland, L; Fedorowicz, Z; van der Linden, MM; van Zuuren, EJ	1
Fowler, J; Jarratt, M; Leoni, M; Liu, Y; Meadows, K; Moore, A; Pollack, A; Steinhoff, M	1
Fallen, RS; Gooderham, M	1

Reviews

4 review(s) available for quinoxalines and Rosacea

Article	Year
Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert review of clinical pharmacology, 2014, Volume: 7, Issue:5 Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Erythema; Humans; Quality of Life; Quinoxalines; Rosacea; Treatment Outcome	2014
Rosacea: new and emerging treatments. Drugs, 2014, Volume: 74, Issue:13 Topics: Administration, Cutaneous; Brimonidine Tartrate; Dermatologic Agents; Drug Design; Humans; Ivermectin; Oxymetazoline; Quality of Life; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea	2014
Brimonidine for erythema caused by rosacea. Drug and therapeutics bulletin, 2014, Volume: 52, Issue:12 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Contraindications; Drug Costs; Drug Interactions; Erythema; Humans; Quinoxalines; Rosacea	2014
Interventions for rosacea. The Cochrane database of systematic reviews, 2015, Apr-28, Issue:4 Topics: Anti-Infective Agents; Brimonidine Tartrate; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Female; Humans; Ivermectin; Male; Metronidazole; Middle Aged; Ophthalmic Solutions; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Tetracycline	2015

Trials

5 trial(s) available for quinoxalines and Rosacea

Article	Year
Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. Journal of drugs in dermatology : JDD, 2013, Jun-01, Volume: 12, Issue:6 Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Facial Dermatoses; Female; Follow-Up Studies; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult	2013
Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:1 Topics: Administration, Cutaneous; Administration, Topical; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Erythema; Face; Female; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Social Behavior; Treatment Outcome; Young Adult	2014
Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. The British journal of dermatology, 2014, Volume: 171, Issue:1 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Area Under Curve; Biological Availability; Brimonidine Tartrate; Drug Administration Schedule; Facial Dermatoses; Female; Gels; Humans; Male; Ophthalmic Solutions; Quinoxalines; Rosacea	2014
Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:6 Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Erythema; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult	2014
Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. The British journal of dermatology, 2012, Volume: 166, Issue:3 Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome; Young Adult	2012

Other Studies

10 other study(ies) available for quinoxalines and Rosacea

Article	Year
Brimonidine gel (Mirvaso) for rosacea. The Medical letter on drugs and therapeutics, 2013, Oct-14, Volume: 55, Issue:1427 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Drug Approval; Gels; Humans; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Treatment Outcome; United States; United States Food and Drug Administration	2013
Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy? Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:6 Suppl 1 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Erythema; Humans; Oxymetazoline; Quinoxalines; Rosacea; Sympathetic Nervous System; Vasodilation	2013
Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. Journal of the American Academy of Dermatology, 2014, Volume: 70, Issue:2 Topics: Administration, Cutaneous; Adult; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Female; Follow-Up Studies; Gels; Humans; Pain; Quinoxalines; Recurrence; Risk Assessment; Rosacea; Sampling Studies; Severity of Illness Index	2014
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis, 2014, Volume: 93, Issue:3 Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Infective Agents; Brimonidine Tartrate; Consensus; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Erythema; Humans; Metronidazole; Quinoxalines; Rosacea; Severity of Illness Index; Societies, Medical	2014
Brimonidine effective but may lead to significant rebound erythema. Journal of the American Academy of Dermatology, 2014, Volume: 70, Issue:5 Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Erythema; Female; Humans; Quinoxalines; Rosacea; Vasoconstriction	2014
Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:7 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Female; Gels; Humans; Quinoxalines; Rosacea; Severity of Illness Index; Tomography, Optical Coherence; Treatment Outcome	2014
New agents for the treatment of erythematotelangiectatic rosacea. Cutis, 2014, Volume: 94, Issue:1 Topics: Brimonidine Tartrate; Clinical Trials as Topic; Dermatologic Agents; Gels; Humans; Oxymetazoline; Quinoxalines; Rosacea; Treatment Outcome	2014
[Erythema of rosacea: a new and effective treatment]. Annales de dermatologie et de venereologie, 2014, Volume: 141 Suppl 2 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Erythema; Female; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome	2014
Optimizing the use of topical brimonidine in rosacea management: panel recommendations. Journal of drugs in dermatology : JDD, 2015, Volume: 14, Issue:1 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Dermatologic Agents; Gels; Humans; Quinoxalines; Rosacea; Treatment Outcome	2015
Rosacea: update on management and emerging therapies. Skin therapy letter, 2012, Volume: 17, Issue:10 Topics: Administration, Cutaneous; Adrenergic Agents; Anti-Infective Agents; Antiparasitic Agents; Brimonidine Tartrate; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Female; Humans; Ivermectin; Male; Metronidazole; Oxymetazoline; Quality of Life; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Sulfacetamide; Treatment Outcome	2012